Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis

Sponsor

Université de Sherbrooke (Other)

Overall Status

Unknown status

CT.gov ID

NCT02913365

Collaborator

(none)

1,000

Enrollment

Location

Duration (Months)

17.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The study consist of a retrospective analysis of the etiologies, investigations and outcomes of patients presenting between 2005 to 2010 with hemoptysis in a North-American Tertiary center.

Condition or Disease	Intervention/Treatment	Phase
Hemoptysis Haemoptysis Lung Disease Pneumonia Tuberculosis Bronchiectasis Respiratory Tract Infections Respiratory Tract Diseases Bronchitis Mycobacterium Infections Bronchial Disease Pulmonary Hemorrhage Signs and Symptoms Signs and Symptoms, Respiratory Pathologic Processes Mycosis Hemorrhage Lung Cancer Pulmonary Embolism Arteriovenous Fistula

Detailed Description

RATIONALE:

Hemoptysis, mild or massive, is worrisome for both patients and physicians. The management is different depending on the causes, which are not well defined for the North American population. Despite the fact that this symptom is commonly reported in clinic, there are only a few studies published on this subject in the North-American population. Tuberculosis was a frequent cause of hemoptysis described in populations overseas, which seems less prevalent in the investigators center.

Also, there are no known official guidelines regarding the investigation and management of hemoptysis. The investigators hypothesized that the use of modern technology in a North American population may result in different findings and provide a more accurate diagnostic approach.

Therefore, the study compares the different etiologies of hemoptysis and investigation modalities used in patients presenting in a North-American tertiary center.

METHOD:

The investigators did a retrospective analysis of medical chart from patients with hemoptysis who visited the investigators center between 2005 and 2010. Each visit has been reviewed individually to describe the characteristics of patients, etiologies of hemoptysis and investigation modalities used. All-cause mortality at 2 years was also recorded.

Descriptive statistical analyses will conducted on the data available.

Study Design

Study Type:

Observational

Anticipated Enrollment :

1000 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis in a North-American Tertiary Center at the Beginning of the 21st Century

Study Start Date :

Oct 1, 2012

Anticipated Primary Completion Date :

Jun 1, 2017

Anticipated Study Completion Date :

Jun 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Patients presenting with hemoptysis Patients over 18 years of age presenting with hemoptysis at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between the periods of 2005 to 2010.

Outcome Measures

Primary Outcome Measures

Etiologies of hemoptysis [5 years]
Defining the prevalence of pulmonary diseases by measuring the percentage of patients presenting with hemoptysis caused by lung cancer, bronchiectasis, pulmonary embolism, arteriovenous fistula, pneumonia, bronchitis, tuberculosis, mycosis, heart failure, pseudohemoptysis, cryptogenic and other causes.

Secondary Outcome Measures

Sensitivity of chest X-ray, chest CT-scan and CT-angiography, bronchoscopy, ventilation-perfusion with single-photon emission computed tomography and pulmonary angiography. [5 years]
Determining the sensitivity in obtaining the etiology of the hemoptysis episode of each diagnostic modality that follows : chest X-ray, chest CT-scan and CT-angiography, bronchoscopy, ventilation-perfusion with single-photon emission computed tomography and pulmonary angiography in the diagnosis of different etiologies of hemoptysis.
All-cause mortality at 2 years [2 years]
All-cause mortality at 2 years after the diagnosis of hemoptysis.
Smoking status [Day 1]
Determining the percentage of patients who : never smoked, is an active smoker, former smoker or unknown status.
Age [Day 1]
Determining the average age of the enrolled patients.
Gender [Day 1]
Determining the percentage of each gender of the enrolled patients.
International Normalized Ratio [Day 1]
Determining the median of the international normalized ratio (INR).
Partial Thromboplastin Time [Day 1]
Determining the median of the partial thromboplastin time (PTT).
Platelet count [Day 1]
Determining the average of the platelet count measured per microliter of blood.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Any patient over the age of 18 presenting with:

A diagnosis of hemoptysis on an outpatient basis.
A diagnosis of hemoptysis during consultation in the emergency department.
A diagnosis of hemoptysis on the admission sheet.
A diagnosis of hemoptysis when hospitalized.
A complication of hemoptysis
Hemoptysis on the report of the bronchoscopy, chest computed tomography, pulmonary angiography, ventilation-perfusion single-photon emission computed tomography or blood transfusion.